No evidence for BRAF-V600E mutations in gastroeosophageal tumors: results from a high-throughput analysis of 534 cases using a mutation-specific antibody
Background: BRAF-V600E mutations are found in a broad spectrum of cancer types and can be successfully targeted by specific therapeutic compounds. Little data on the prevalence of BRAF-V600E mutations in tumors of the upper gastrointestinal tract are available. Materials and Methods: We constructed...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2013
|
| In: |
Applied immunohistochemistry & molecular morphology
Year: 2013, Volume: 21, Issue: 5, Pages: 426-430 |
| ISSN: | 1533-4058 |
| DOI: | 10.1097/PAI.0b013e31827ce693 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/PAI.0b013e31827ce693 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/appliedimmunohist/Abstract/2013/10000/No_Evidence_for_BRAF_V600E_Mutations_in.8.aspx 
|
| Author Notes: | Matthias Preusser, Anna S. Berghoff, David Capper, Andreas von Deimling, Florian Maroske, Thomas Brodowicz, Michael Hejna, Peter Birner, Sebastian F. Schoppmann |
| Summary: | Background: BRAF-V600E mutations are found in a broad spectrum of cancer types and can be successfully targeted by specific therapeutic compounds. Little data on the prevalence of BRAF-V600E mutations in tumors of the upper gastrointestinal tract are available. Materials and Methods: We constructed tissue microarrays of formalin-fixed and paraffin-embedded specimens of 534 gastroesophageal tumors (119 squamous cell cancers and 72 adenocarcinomas of the esophagus, 63 cancers of the gastroesophageal junction/cardia, 199 gastric cancers of the corpus or antrum, 81 gastric gastrointestinal stromal tumors) and performed anti-BRAF-V600E immunostaining using the mutation-specific antibody VE1. As control tissue we used 3 melanoma cases with confirmed BRAF-V600E mutation and distinct VE1 immunostaining. Results: None of the gastroesophageal tumor cases showed a positive immunostaining signal. Conclusions: BRAF-V600E mutation is not a relevant oncogenic driver in gastroesophageal tumors. Immunohistochemical analysis using mutation-specific antibodies on tissue microarrays is a feasible, time-efficient and cost-efficient approach to high-throughput screening for specific mutations in large tumor series. |
|---|---|
| Item Description: | Gesehen am 08.12.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1533-4058 |
| DOI: | 10.1097/PAI.0b013e31827ce693 |